Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QM6J | ISIN: US81728A1088 | Ticker-Symbol: 407
Tradegate
21.05.24
09:23 Uhr
1,345 Euro
+0,045
+3,46 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSEI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SENSEI BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2301,29023:00
1,2301,29522:00

Aktuelle News zur SENSEI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Sensei Biotherapeutics, Inc. - 10-Q, Quarterly Report6
09.05.Sensei Biotherapeutics GAAP EPS of -$0.326
09.05.Sensei Biotherapeutics, Inc. - 8-K, Current Report4
09.05.Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights105- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation...
► Artikel lesen
03.05.CTMX, HSDT and SNSE are among premarket gainers23
02.05.JAGX, SNSE and BON among mid-day movers163
24.04.Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting42
12.04.Sensei Biotherapeutics, Inc. - 8-K, Current Report11
09.04.Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference8
04.04.Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment128BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...
► Artikel lesen
02.04.Sensei Biotherapeutics, Inc. - 8-K, Current Report6
26.03.World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain374LONDON, March 26, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first...
► Artikel lesen
26.03.Telix Pharmaceuticals Limited; Lightpoint Surgical Limited: World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain9
22.03.Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium15
06.03.Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences15
29.02.Sensei Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans15
28.02.Sensei Biotherapeutics reports FY results10
28.02.Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights288- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline...
► Artikel lesen
28.02.Sensei Biotherapeutics, Inc. - 8-K, Current Report3
08.02.Sensei Biotherapeutics, Inc. - 8-K, Current Report12
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2